TP53 and neoplasm: Importantly, tumor cells with defined mutations retain their characteristic responses to chemotherapeutics in the VMT platform – SW620 cells, which carry a p53 mutation were considerably more resistant to 5-FU than HCT116, which express wild-type p5348.